Accepted: 17 January 2020
First Online: 28 February 2020
: S.L.’s institution receives research funding from Bristol-Myers Squibb, Eli Lilly, Genentech, Merck, Novartis, Pfizer, Puma Biotechnology and Roche. S.L. has acted as a non-compensated consultant of AstraZeneca, Bristol-Meyers Squibb, Merck, Novartis, Pfizer, Roche-Genentech and Seattle Genetics. P.J.N. receives research funding from Advaxis, Allergan, Bristol-Myers Squibb, Compugen, Juno-Celgene and Roche-Genentech. The other authors declare no competing interests.